FINWIRES · TerminalLIVE
FINWIRES

Radiopharm Theranostics Receives AU$5.9 Million R&D Tax Refund for Fiscal Year 2025

By

Radiopharm Theranostics (ASX:RAD) received its research and development (R&D) tax refund for the fiscal year 2025, totalling AU$5.9 million, including AU$104,475 in interest, according to a Friday Australian bourse filing.

The refund will provide funding for continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications, it added.

What else is happening in Asia?